Edition:
United States

Precision Therapeutics Inc (AIPT.OQ)

AIPT.OQ on NASDAQ Stock Exchange Capital Market

1.01USD
25 May 2018
Change (% chg)

$0.01 (+1.00%)
Prev Close
$1.00
Open
$0.99
Day's High
$1.18
Day's Low
$0.99
Volume
124,166
Avg. Vol
87,443
52-wk High
$2.50
52-wk Low
$0.81

Latest Key Developments (Source: Significant Developments)

Precision Therapeutics Q1 Loss Per Share $0.15
Tuesday, 15 May 2018 04:15pm EDT 

May 15 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.15.Q1 REVENUE $411,600 VERSUS $175,200.  Full Article

Precision Therapeutics Q4 Loss Per Share $0.43
Monday, 2 Apr 2018 04:15pm EDT 

April 2 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.43.Q4 REVENUE $220,300 VERSUS $139,600.  Full Article

Precision Therapeutics Unit Announces License Agreement With Cellbridge Inc
Wednesday, 21 Mar 2018 08:30am EDT 

March 21 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED.PRECISION THERAPEUTICS INC - CO'S UNIT, TUMORGENESIS SECURED A LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED​.  Full Article

Precision Therapeutics Forms Tumorgenesis Subsidiary
Tuesday, 27 Feb 2018 08:30am EST 

Feb 27 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS FORMS TUMORGENESIS INC. SUBSIDIARY TO FOCUS ON THE NEXT GENERATION OF PATIENT DERIVED TUMOR MODELS.‍FORMED TUMORGENESIS TO DEVELOP A NEW, RAPID APPROACH TO GROWING TUMORS IN LABORATORY​.‍TESTING OF TUMORGENESIS PDX TUMORS TO TAKE PLACE IN COLLABORATION WITH HELOMICS, IN WHICH CO HAS 20% EQUITY STAKE​.IN NEGOTIATIONS WITH MEDICAL TECHNOLOGY COS TO LICENSE THEIR TECHNOLOGY TO ADVANCE TUMORGENESIS'S STRATEGIC PLAN​.  Full Article

Skyline Medical Says Sold Ten Streamway Systems In 2017
Wednesday, 3 Jan 2018 05:15pm EST 

Jan 3 (Reuters) - Skyline Medical Inc ::SKYLINE MEDICAL INC - COMPANY SOLD TEN STREAMWAY SYSTEMS IN 2017, FIVE OF WHICH WERE SOLD IN FOURTH FISCAL QUARTER OF 2017.SKYLINE MEDICAL INC - A FURTHER SIX STREAMWAY UNITS HAVE BEEN BOOKED FOR SALE IN JANUARY 2018.  Full Article

Skyline Medical And Helomics Expand Into Next Generation Sequencing For Personalized Medicine
Wednesday, 20 Dec 2017 08:30am EST 

Dec 20 (Reuters) - Helomics Corp ::SKYLINE MEDICAL AND HELOMICS EXPAND INTO NEXT GENERATION SEQUENCING FOR PERSONALIZED MEDICINE.SKYLINE MEDICAL INC - EXPANDING INTO NEXT GENERATION SEQUENCING THROUGH LICENSING OF AN NGS PLATFORM MISEQDX, FROM ILLUMINA.SKYLINE MEDICAL INC - "WE FULLY EXPECT NGS PLATFORM TO DRIVE REVENUE FROM NEW PARTNERSHIPS EARLY IN 2018".  Full Article

Skyline Medical Says Acquiring Up To 25 Pct Stake In Helomics
Tuesday, 19 Dec 2017 05:30pm EST 

Dec 19 (Reuters) - Skyline Medical Inc ::SKYLINE MEDICAL ACQUIRING UP TO 25% EQUITY STAKE IN HELOMICS CORPORATION, A PRECISION DIAGNOSTICS COMPANY.SKYLINE MEDICAL - PURCHASING PREFERRED STOCK CONVERTIBLE INTO 20% OF OUTSTANDING STOCK OF HELOMICS FOR 1.1 MILLION SHARES OF NEWLY ISSUED CO'S STOCK.  Full Article

Skyline Medical Files For Resale Of Up To 1.9 Mln Shares By Selling Stockholder
Friday, 8 Dec 2017 05:40pm EST 

Dec 8 (Reuters) - Skyline Medical Inc ::SKYLINE MEDICAL INC FILES FOR RESALE OF UP TO 1.9 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDER - SEC FILING.  Full Article

Skyline Medical and Helomics Announce Joint Strategic Partnership With GLG Pharma
Tuesday, 28 Nov 2017 08:30am EST 

Nov 28 (Reuters) - Helomics Corp ::SKYLINE MEDICAL AND HELOMICS ANNOUNCE A JOINT STRATEGIC PARTNERSHIP WITH GLG PHARMA.SKYLINE MEDICAL - ‍NEW PARTNERSHIP TO FILE FOR EUROPEAN GRANT APPLICATION TO EXPAND GLG'S AND SKYLINE-HELOMICS VENTURE'S PRODUCT OFFERING​ ACROSS EUROPE.  Full Article

Skyline Medical, Helomics Corp sign joint venture to commercialize D-CHIP platform
Wednesday, 15 Nov 2017 08:30am EST 

Nov 15 (Reuters) - Helomics Corp :Skyline Medical and Helomics Corporation sign joint venture term sheet to build-out and commercialize the D-CHIP platform.Skyline Medical Inc - ‍joint venture is subject to terms and conditions, including further due diligence and financing of new entity​.Skyline Medical Inc - ‍signed a term sheet with Helomics Corporation​.Skyline Medical Inc - ‍deal to leverage Helomics D-CHIP platform to develop and market new approaches for personalized cancer diagnosis and care​.Skyline Medical Inc - ‍skyline Medical will own 51 pct of joint venture, with Helomics owning remaining 49 pct​.Skyline Medical Inc - operations of JV will be managed by Helomics subject to direction and oversight of joint venture's board of directors​.  Full Article

BRIEF-Precision Therapeutics Q1 Loss Per Share $0.15

* PRECISION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

No consensus analysis data available.